


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (1):



wherein:

A is phenylene or heteroarylene;

n is 0, 1, or 2;

m is 0, 1, or 2;


R¹ is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-C₁₋₄alkylcarbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, sulphamoyl, *N*-C₁₋₄alkylsulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, -S(O)_bC₁₋₄alkyl (wherein b is 0, 1, or 2), C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, hydroxyC₁₋₄alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, and trifluoromethoxy; or

when n is 2, the two R¹ groups, together with the carbon atoms of A to which they are attached, may form a 4- to 7-membered ring, optionally containing 1 or 2 heteroatoms independently selected from O, S, and N, and optionally being substituted with one or two methyl groups;

R⁴ is hydrogen or halo independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, and C₁₋₄alkanoyl;

r is 1 or 2;

when r is 1 the group




is a substituent on carbon (2);


when r is 2 (thereby forming a six membered ring) the same group is a substituent on carbon (2) or on carbon (3);

Y is $-NR^2R^3$ or $-OR^3$;

R^2 and R^3 are independently selected from hydrogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkanoyl, carbamoyl, C_{3-7} cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C_{1-4})alkyl, heterocyclyl, aryl, C_{1-4} alkyl [optionally substituted with 1 or 2 R^8 groups], $-COR^8$, $-SO_bR^8$ (wherein b is 0, 1, or 2), and groups of the formulae B and B'



(B)



(B')

wherein y is 0 or 1, t is 0, 1, 2, or 3 and u is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen; or

wherein NR^2R^3 may form a 4- to 7-membered saturated, partially saturated, or unsaturated ring, optionally containing 1, 2, or 3 additional heteroatoms independently selected from N, O, and S, wherein any $-CH_2-$ may optionally be replaced by $-C(=O)-$, and any N or S atom may optionally be oxidized to form an N-oxide, SO, or SO_2 group respectively, and wherein the ring is optionally substituted with 1 or 2 substituents independently selected from halo, cyano, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy, and C_{1-4} alkylS(O)_b- (wherein b is 0, 1, or 2);

R^8 is independently selected from hydrogen, hydroxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{1-4} alkoxy, cyano(C_{1-4})alkyl, amino(C_{1-4})alkyl [optionally substituted on nitrogen with 1 or 2 groups selected from C_{1-4} alkyl, hydroxy, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, $-CO_2C_{1-4}$ alkyl, aryl, and aryl(C_{1-4})alkyl], halo(C_{1-4})alkyl, dihalo(C_{1-4})alkyl, trihalo(C_{1-4})alkyl, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl, hydroxy C_{1-4} alkoxy, 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, aryl, heterocyclyl, (heterocyclyl) C_{1-4} alkyl, C_{3-7} cycloalkyl (optionally substituted with 1 or 2 hydroxy groups, C_{1-4} alkyl, or $-C(O)OC_{1-4}$ alkyl), C_{1-4} alkanoyl, C_{1-4} alkylS(O)_b- (wherein b is 0, 1, or 2), C_{3-6} cycloalkylS(O)_b- (wherein b is 0, 1, or 2), arylS(O)_b- (wherein b is 0, 1, or 2), heterocyclylS(O)_b- (wherein b is 0, 1, or 2), benzylS(O)_b- (wherein b is 0, 1, or 2), C_{1-4} alkylS(O)_c(C_{1-4})alkyl (wherein c is 0, 1, or 2), $-N(OH)CHO$, $-C(=N-OH)NH_2$, $-C(=N-OH)NHC_{1-4}$ alkyl, $-C(=N-OH)N(C_{1-4}alkyl)_2$, $-C(=N-OH)NHC_{3-6}$ cycloalkyl, $-C(=N-OH)N(C_{3-6}$ cycloalkyl)₂, $-COCOOR^9$, $-C(O)N(R^9)(R^{10})$,

-NHC(O)R⁹, -C(O)NHSO₂(C₁₋₄alkyl), -NHSO₂R⁹, (R⁹)(R¹⁰)NSO₂-, -COCH₂OR¹¹, (R⁹)(R¹⁰)N-, -COOR⁹, -CH₂OR⁹, -CH₂COOR⁹, -CH₂OCOR⁹, -CH₂CH(CO₂R⁹)OH, -CH₂C(O)NR⁹R¹⁰, -(CH₂)_wCH(NR⁹R¹⁰)CO₂R⁹ (wherein w is 1, 2 or 3), and -(CH₂)_wCH(NR⁹R¹⁰)CO(NR⁹R¹⁰) (wherein w is 1, 2, or 3);

R⁹, R^{9'}, R¹⁰, and R^{10'} are independently selected from hydrogen, hydroxy, C₁₋₄alkyl (optionally substituted with 1 or 2 R¹³), C₂₋₄alkenyl, C₃₋₇cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C₁₋₄)alkyl, trihaloalkyl, aryl, heterocyclyl, heterocyclyl(C₁₋₄alkyl), and -C(=O)O(C₁₋₄)alkyl; or

R⁹ and R¹⁰ together with the nitrogen to which they are attached, or R^{9'} and R^{10'} together with the nitrogen to which they are attached, form a 4- to 6-membered ring where the ring is optionally substituted on carbon with 1 or 2 substituents independently selected from oxo, hydroxy, carboxy, halo, nitro, cyano, carbonyl, C₁₋₄alkoxy, and heterocyclyl; or the ring may be optionally substituted on two adjacent carbons with -O-CH₂-O- to form a cyclic acetal wherein one or both of the hydrogens of the -O-CH₂-O- group may be replaced by a methyl;

R¹³ is selected from halo, trihalomethyl, and C₁₋₄alkoxy; and

R¹¹ is independently selected from hydrogen, C₁₋₄alkyl, and hydroxyC₁₋₄alkyl; or a pharmaceutically acceptable salt or prodrug thereof.

2. (original) A compound of claim 1, wherein:

R² and R³ are independently selected from hydrogen, hydroxy, C₁₋₄alkyl [optionally substituted with 1 or 2 R⁸ groups], C₃₋₇cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C₁₋₄)alkyl, phenyl, morpholino, morpholinyl, piperidino, piperidyl, pyridyl, pyranlyl, pyrrolyl, imidazolyl, thiazolyl, thienyl, thiadiazolyl, piperazinyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl, pyrazolinyl, isoxazolyl, 4-oxopyridyl, 2-oxopyrrolidyl, 4-oxothiazolidyl, furyl, thienyl, oxazolyl, 1,3,4-oxadiazolyl, and 1,2,4-oxadiazolyl, tetrahydrothiopyranlyl, 1-oxotetrahydrothiopyranlyl, 1,1-dioxotetrahydrothiopyranlyl, -COR⁸, and -SO₂R⁸ (wherein b is 0, 1, or 2);

R⁸ is independently selected from hydrogen, hydroxy, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkoxy, hydroxyC₁₋₄alkoxy, C₁₋₄alkyl, , amino(C₁₋₄)alkyl [optionally substituted on nitrogen with 1 or 2 groups selected from C₁₋₄alkyl, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, -CO₂C₁₋₄alkyl, aryl, and aryl(C₁₋₄)alkyl], C₂₋₄alkenyl, C₃₋₇cycloalkyl (optionally substituted with -C(O)OC₁₋₄alkyl), 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, halo(C₁₋₄)alkyl, dihalo(C₁₋₄)alkyl, trihalo(C₁₋₄)alkyl, hydroxy(C₁₋₄)alkyl,

dihydroxy(C₁₋₄)alkyl, cyano(C₁₋₄)alkyl, heterocyclyl, heterocyclylC₁₋₄alkyl, aryl, C₁₋₄alkylS(O)_b⁻ (wherein b is 0, 1, or 2), C₃₋₆cycloalkylS(O)_b⁻ (wherein b is 0, 1, or 2), arylS(O)_b⁻ (wherein b is 0, 1, or 2), heterocyclylS(O)_b⁻ (wherein b is 0, 1, or 2), benzylS(O)_b⁻ (wherein b is 0, 1, or 2), C₁₋₄alkylS(O)_c(C₁₋₄)alkyl (wherein c is 0, 1, or 2), -CH₂CH(NR⁹R¹⁰)CO(NR⁹R¹⁰), -CH₂OR⁹, (R⁹)(R¹⁰)N-, -COOR⁹, -CH₂COOR⁹, -C(O)N(R⁹)(R¹⁰), -CH₂CH(CO₂R⁹)OH, -CH₂CONR⁹R¹⁰, -CH₂CH(NR⁹R¹⁰)CO₂R⁹, and -CH₂OCOR⁹;

R⁹, R^{9'}, R¹⁰, and R^{10'} are independently selected from hydrogen, C₁₋₄alkyl (optionally substituted with 1 or 2 R¹³), C₃₋₇cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), -C(=O)O^tBu, C₂₋₄alkenyl, cyano(C₁₋₄)alkyl, phenyl (optionally substituted with 1 or 2 groups selected from nitro, halo, hydroxy, and cyano); or

R⁹ and R¹⁰ together with the nitrogen to which they are attached, or R^{9'} and R^{10'} together with the nitrogen to which they are attached, form a 4- to 6-membered ring where the ring is optionally substituted on carbon with 1 or 2 substituents independently selected from oxo, hydroxy, carboxy, halo, nitro, cyano, carbonyl, and C₁₋₄alkoxy; or the ring may be optionally substituted on two adjacent carbons with -O-CH₂-O- to form a cyclic acetal wherein one or both of the hydrogens of the -O-CH₂-O- group may be replaced by a methyl; and

R¹³ is selected from halo, trihalomethyl, and C₁₋₄alkoxy;

or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

3. (original) A compound of claim 1, wherein:

R² and R³ are independently selected from hydrogen, C₁₋₄alkyl [optionally substituted with 1 or 2 R⁸ groups], -COR⁸ and -SO_bR⁸ (wherein b is 0, 1, or 2);

R⁸ is independently selected from hydrogen, hydroxy, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkyl, amino(C₁₋₄)alkyl [optionally substituted on nitrogen with 1 or 2 groups selected from C₁₋₄alkyl, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, -CO₂C₁₋₄alkyl, phenyl, and aryl(C₁₋₄)alkyl], C₂₋₄alkenyl, C₃₋₇cycloalkyl (optionally substituted with -C(O)OC₁₋₄alkyl), 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, halo(C₁₋₄)alkyl, trihalo(C₁₋₄)alkyl, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, cyano(C₁₋₄)alkyl, furyl (optionally substituted on carbon with 1 or 2 nitro groups), thienyl (optionally substituted on carbon with 1 or 2 nitro groups), morpholino, furyl(C₁₋₄)alkyl (wherein furyl is optionally substituted on carbon with 1 or 2 nitro groups), thienyl(C₁₋₄)alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl, pyridyl, tetrahydrofuryl, tetrahydropyranyl, 1-oxo-tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally substituted with 1 or 2 groups selected from nitro, halo, cyano, hydroxy, and C₁₋₄alkyl), pyrazinyl,

piperazinyl, 4-methylpiperazino, $C_{1-4}alkylS(O)_b-$ (wherein b is 0, 1, or 2), $C_{3-6}cycloalkylS(O)_b-$ (wherein b is 0, 1, or 2), $arylS(O)_b-$ (wherein b is 0, 1, or 2), heterocyclylS(O)_b- (wherein b is 0, 1, or 2), $-CH_2CH(NR^9R^{10})CO(NR^9R^{10})$, $-CH_2OR^9$, $(R^9)(R^{10})N-$, $-COOR^9$, $-CH_2COOR^9$, $-C(O)N(R^9)(R^{10})$, $-CH_2CH(CO_2R^9)OH$, $-CH_2CONR^9R^{10}$, $-CH_2CH(NR^9R^{10})CO_2R^9$, and $-CH_2OCOR^9$; and

R^9 , R^9 , R^{10} , and R^{10} are independently selected from hydrogen, $C_{1-4}alkyl$ (optionally substituted with 1 or 2 hydroxy groups), $C_{2-4}alkenyl$, and phenyl (optionally substituted with 1 or 2 groups selected from nitro, halo, hydroxy, and cyano);

or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

4. (original) A compound of claim 1, wherein Y is NR^2R^3 , or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.


5. (original) A compound of claim 1, wherein Y is OR^3 , or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

6. (original) A compound of claim 1, wherein m is 1 and R^4 is chlorine, or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

7. (original) A compound of claim 1, wherein A is phenylene, or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

8. (original) A compound of claim 1, wherein A is heteroarylene, or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

9. (original) A compound of claim 1, which is a compound of formula (1A):



(1A)

or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

10. (original) A compound of claim 1, selected from:

5-chloro-2-[*N*-(1-hydroxyindan-2-yl)carbamoyl]indole;

5-chloro-*N*-{[(1*R*,2*R*)-1-[(methylsulfonyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

N-{[(1*R**, 2*R**)-1-[(2-carboxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide};

5-chloro-*N*-{[(1*R*,2*R*)-1-[(3-methoxypropanoyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

N-{[(1*R*,2*R*)-1-(acetylamino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide};

5-chloro-*N*-{[(1*R*,2*R*)-1-(*tert*-butoxycarbonylaminoacetamido)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

N-{[(1*R*,2*R*)-1-[[3-(*tert*-butoxycarbonylamino)-4-oxopentanoyl]amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide};

N-{[(1*R*,2*R*)-1-[(2-carbamoylacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide};

N-{[(1*R*,2*R*)-1-[(2-carboxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide};

5-chloro-*N*-{[(1*R*,2*R*)-1-[(hydroxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[[3-hydroxy-2-(hydroxymethyl)propanoyl]amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

N-{[(1*R*,2*R*)-1-[[3-(3-amino-3-carbamoylpropanoyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide};

N-{[(1*R*,2*R*)-1-[(aminoacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide};

5-chloro-*N*-{[(1*S*,2*S*)-1-[(methylsulfonyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

5-chloro-*N*-{1-[(hydroxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

5-chloro-*N*-{[(1*R*,2*R*)-1-[[[(2-hydroxyethyl)(methyl)amino]acetyl]amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

5-chloro-*N*-{[(1*R*,2*R*)-1-[[[(2-hydroxyethyl)(phenylmethyl)amino]acetyl] amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

5-chloro-*N*-{[(1*R*,2*R*)-1-[[[(3-hydroxypiperidin-1-yl)acetyl]amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide};

5-chloro-*N*-((1*R*,2*R*)-1-(((3-hydroxypyrrolidin-1-yl)acetyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-(((bis(2-hydroxyethyl)amino)acetyl)amino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;

N-{1-[(aminoacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;

N-{1-(((3*S*)-3-amino-3-carboxypropanoyl)amino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide;

5-chloro-*N*-((1*R*,2*R*)-1-((chloromethyl)sulfonyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-{1-((trifluoromethyl)sulfonyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-{1-[(cyanomethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-((1*R*,2*R*)-1-((1*H*-tetrazol-5-ylmethyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-[(2-amino-2-oxoethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloro-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-(carboxymethylamino)-2,3-dihydro-1*H*-inden-2-yl)-5-chloroindole-2-carboxamide;

N-((1*S*,2*S*)-1-[acetyl(2-thienylmethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloro-1*H*-indole-2-carboxamide;

N-((1*S*,2*S*)-1-[*N*-acetyl-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloroindole-2-carboxamide;

N-((1*S*,2*S*)-1-[*N*-acetyl-*N*-[2-(ethoxycarbonyl)cycloprop-1ylmethyl]amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloroindole-2-carboxamide;

N-((1*R*,2*R*)-1-[*N*-acetyl-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloroindole-2-carboxamide;

N-((1*R*,2*R*)-1-[bis-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloroindole-2-carboxamide;

N-((1*R*,2*R*)-1-[Acetyl(2-amino-2-oxoethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloro-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-[*N*-(2-acetoxyacetyl)-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-5-chloroindole-2-carboxamide;

5-chloro-*N*-((1*R*,2*R*)-1-(2,5-dioxomorpholin-4-yl)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide; and

5-chloro-*N*-((1*R*,2*R*)-1-[[[(2*R*)-2,3-dihydroxypropyl]amino]-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;


or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

11. (original) A pharmaceutical composition which comprises a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof in association with a pharmaceutically acceptable diluent or carrier.


12. (original) A method for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, comprising administering a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.

13. (original) A method for the treatment of type 2 diabetes in a warm-blooded animal, comprising administering a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.

14. (original) A process for the preparation of a compound of claim 1, which process comprises: reacting an acid of the formula (2)



or an activated derivative thereof; with an amine of formula (3)



and thereafter if necessary

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups; or
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

15 (new) A compound of claim 1, selected from:

5-chloro-2-(*N*-(1-[*N*-(1,1-dimethylethoxy)carbonylamino]indan-2-yl)carbamoyl)indole;
rac-*N*-(1-amino-2,3-dihydro-1*H*-inden-2-yl)-5-chloro-1*H*-indole-2-carboxamide; and
N-[(1*R*,2*R*)-1-amino-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide.